PYXIS ONCOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
PYXIS ONCOLOGY INC. - More news...
PYXIS ONCOLOGY INC. - More news...
- Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
- Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
- Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
- Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
- Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
- Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
- Pyxis Oncology to Participate in Two Upcoming Investor Conferences
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
- Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
- Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
- Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
- Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
- Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
- Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
- Pyxis Oncology Announces $50 Million Private Placement
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
- Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
- Pyxis Oncology to Participate in Two Upcoming Investment Conferences
- Pyxis Oncology Successfully Completes Acquisition of Apexigen
- Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
